Kura Oncology ((KURA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Kura Oncology is conducting a Phase 1 study titled ‘Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia.’ The study aims to evaluate the safety, tolerability, and early efficacy of Ziftomenib, an investigational drug, in combination with standard-of-care treatments for patients with acute myeloid leukemia (AML) with specific genetic mutations. This study is significant as it addresses treatment options for both newly diagnosed and relapsed/refractory AML patients.
Intervention/Treatment: The study tests Ziftomenib, an investigational drug, in combination with other drugs like Venetoclax, Azacitidine, Daunorubicin, Cytarabine, and Quizartinib. These combinations aim to enhance treatment efficacy for AML patients with specific genetic profiles.
Study Design: This interventional study is non-randomized with a parallel assignment model. It is open-label, meaning no masking is involved, and its primary purpose is treatment. Participants are grouped based on specific genetic mutations and treatment history.
Study Timeline: The study began on February 9, 2023, and is currently recruiting. The last update was submitted on October 8, 2025. These dates are crucial for tracking the study’s progress and potential data releases.
Market Implications: The progress of this study could significantly impact Kura Oncology’s stock performance and investor sentiment, especially if early results show promise. The study’s focus on genetic mutations in AML also positions Kura Oncology in a competitive spot within the oncology sector, potentially influencing market dynamics and investor interest.
The study is ongoing, and further details are available on the ClinicalTrials portal.